Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.

Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.

H2N2 Influenza A caused the Asian flu pandemic in 1957, circulated for more than 10 years and disappeared from the human population after 1968. Given that people born after 1968 are naïve to H2N2, that the virus still circulates in wild birds and that this influenza subtype has a proven pandemic tra...

Full description

Bibliographic Details
Main Authors:	Irina Isakova-Sivak, Jørgen de Jonge, Tatiana Smolonogina, Andrey Rekstin, Geert van Amerongen, Harry van Dijken, Justin Mouthaan, Paul Roholl, Victoria Kuznetsova, Elena Doroshenko, Vadim Tsvetnitsky, Larisa Rudenko
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25058039/?tool=EBI

Similar Items

Could Trivalent LAIV Protect Against Both Genetic Lineages of Influenza B Virus?
by: Irina Kiseleva, et al.
Published: (2019-06-01)

Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine.
by: Victoria Matyushenko, et al.
Published: (2017-01-01)

Associated virus-bacterial vaccine based on seasonal LAIV and S. pneumoniae chimeric peptide provide protection against post-influenza pneumococcal infection in mouse model
by: Yulia Desheva, et al.
Published: (2022-12-01)

M2e-based universal influenza vaccines: a historical overview and new approaches to development
by: Daria Mezhenskaya, et al.
Published: (2019-10-01)

Universal Live-Attenuated Influenza Vaccine Candidates Expressing Multiple M2e Epitopes Protect Ferrets against a High-Dose Heterologous Virus Challenge
by: Daria Mezhenskaya, et al.
Published: (2021-06-01)

Development of Cross-Reactive Live Attenuated Influenza Vaccine Candidates against Both Lineages of Influenza B Virus
by: Pei-Fong Wong, et al.
Published: (2024-01-01)

Tackling a novel lethal virus: a focus on H7N9 vaccine development
by: Irina Isakova-Sivak, et al.
Published: (2017-07-01)

Towards a Digital Twin Model for the Management of the Laives Aqueduct
by: Andrea Menapace, et al.
Published: (2022-11-01)

Current Opinion in LAIV: A Matter of Parent Virus Choice
by: Irina Kiseleva
Published: (2022-06-01)

Pathology and Immunity After SARS-CoV-2 Infection in Male Ferrets Is Affected by Age and Inoculation Route
by: Koen van de Ven, et al.
Published: (2021-10-01)

Overview of Nucleocapsid-Targeting Vaccines against COVID-19
by: Alexandra Rak, et al.
Published: (2023-12-01)

Nucleoprotein as a Promising Antigen for Broadly Protective Influenza Vaccines
by: Alexandra Rak, et al.
Published: (2023-11-01)

Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine
by: Daniil Korenkov, et al.
Published: (2018-11-01)

Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests
by: Alexandra Rak, et al.
Published: (2022-09-01)

Live Attenuated Influenza Vaccines engineered to express the nucleoprotein of a recent isolate stimulate human influenza CD8+ T cells more relevant to current infections
by: D. Korenkov, et al.
Published: (2018-04-01)

Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity
by: Sreeja Roy, et al.
Published: (2020-11-01)

Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge
by: Irina Isakova-Sivak, et al.
Published: (2019-07-01)

Prospects of and Barriers to the Development of Epitope-Based Vaccines against Human Metapneumovirus
by: Ekaterina Stepanova, et al.
Published: (2020-06-01)

In Vitro Stimulation with Live SARS-CoV-2 Suggests Th17 Dominance In Virus-Specific CD4+ T Cell Response after COVID-19
by: Igor Kudryavtsev, et al.
Published: (2022-09-01)

Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview
by: Igor Kudryavtsev, et al.
Published: (2022-05-01)

Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site
by: Tatiana Kotomina, et al.
Published: (2018-12-01)

Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model
by: Alexandra Rak, et al.
Published: (2023-01-01)

Comparative Immunogenicity of the 2014–2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children
by: Jann Catherine Ang, et al.
Published: (2019-08-01)

Development of the A/H6N1 influenza vaccine candidate based on A/Leningrad/134/17/57 (H2N2) master donor virus and the genome composition analysis using high resolution melting (HRM)
by: Yulia A. Desheva, et al.
Published: (2016-08-01)

Modified influenza M158–66 peptide vaccination induces non-relevant T-cells and may enhance pathology after challenge
by: Josien Lanfermeijer, et al.
Published: (2023-08-01)

Development of the quadrivalent live attenuated influenza vaccine including two influenza B lineages – Victoria and Yamagata
by: Yu. A. Desheva, et al.
Published: (2016-02-01)

Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines
by: Yulia Desheva, et al.
Published: (2020-05-01)

RDE Treatment Prevents Non-Specific Detection of SARS-CoV-2- and Influenza-Specific IgG Antibodies in Heat-Inactivated Serum Samples
by: Arina Goshina, et al.
Published: (2023-06-01)

A preclinical trial of the reassortant influenza virus vaccinе strain A/17/Quail/Hong Kong/97/84 (H9N2)
by: Yu. A. Desheva, et al.
Published: (2015-08-01)

An intercountry comparison of the impact of the paediatric live attenuated influenza vaccine (LAIV) programme across the UK and the Republic of Ireland (ROI), 2010 to 2017
by: Sinnathamby, MA, et al.
Published: (2023)

Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents
by: Tarride JE, et al.
Published: (2012-10-01)

Immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines
by: I. Losev, et al.
Published: (2019-05-01)

Boosted influenza-specific T cell responses after H5N1 pandemic live attenuated influenza virus (pLAIV) vaccination
by: Yanchun ePeng, et al.
Published: (2015-06-01)

A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats
by: Daria Mezhenskaya, et al.
Published: (2021-02-01)

Two Live Attenuated Vaccines against Recent Low–and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets
by: Larisa Rudenko, et al.
Published: (2018-11-01)

Detection of IFNγ-Secreting CD4<sup>+</sup> and CD8<sup>+</sup> Memory T Cells in COVID-19 Convalescents after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2
by: Victoria Matyushenko, et al.
Published: (2021-07-01)

Ferristatin II Efficiently Inhibits SARS-CoV-2 Replication in Vero Cells
by: Alexey Sokolov, et al.
Published: (2022-02-01)

Influenza Infection in Ferrets with SARS-CoV-2 Infection History
by: Caroline Vilas Boas de Melo, et al.
Published: (2022-12-01)

Safety, Immunogenicity, and Protective Efficacy of a Chimeric A/B Live Attenuated Influenza Vaccine in a Mouse Model
by: Ekaterina Stepanova, et al.
Published: (2021-01-01)

Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.
by: Larisa Rudenko, et al.
Published: (2014-01-01)